On September 9, the National Agency for Medicines and Medical Devices issued a license allowing Polisano Pharmaceuticals to conduct clinical trials.
The company said the bioequivalence trials are mandatory for generic drugs before selling them on the market.
The center allows the simultaneous hospitalization of 26 people, in five wards, and its construction was completed in December 2014.
The new center will conduct clinical trials on molecules developed by Polisano and by other pharmaceutical companies.
Polisano Pharmaceuticals represents an investment of EUR67 million and is part of Polisano group, which provides integrated healthcare services.